help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neidhart, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neidhart, M.

Endocrinology, Vol 125, 2846-2852, Copyright © 1989 by Endocrine Society


ARTICLES

Bromocriptine microcapsules inhibit ornithine decarboxylase activity induced by Freund's complete adjuvant in lymphoid tissues of male rats

M Neidhart
Preclinical Research Department, Sandoz Ltd., Basel, Switzerland.

Arthritis is produced in male rats within 9-10 days after a single injection of Freund's complete adjuvant (FCA) at the base of the tail. When bromocriptine, a dopaminomimetic that suppresses PRL secretion, was given in form of long-acting microcapsules (CBLA) 3 days before FCA, the hind limb swelling was significantly reduced by 70%. Here, we showed that plasma PRL levels were significantly elevated (by 150% over controls) during the 6-day period after FCA, particularly at night. Further, within 1-4 days after FCA inoculation, marked increases in ornithine decarboxylase (ODC) activity occurred in bone marrow, thymus, spleen, and lymph nodes (by 190%, 160%, 80% and 75% over control values, respectively). In FCA-treated rats, the circadian rhythm of thymic ODC showed that an important enhancement of activity occurred during the dark phase, which correlated with the peak of PRL secretion (between 2200-0400 h). Finally, pretreatment with CBLA significantly inhibited the induction of ODC in response to FCA in thymus, spleen, and lymph nodes (by 65%, 80%, and 45%, respectively) and inhibited it more weakly in the bone marrow. This in vivo study leaves little doubt about the existence of a PRL-dependent immuno-stimulatory mechanism, probably involved in the pathogenesis of adjuvant arthritis.


This article has been cited by other articles:


Home page
LupusHome page
S E Walker
Bromocriptine treatment of systemic lupus erythematosus
Lupus, October 1, 2001; 10(10): 762 - 768.
[Abstract] [PDF]


Home page
LupusHome page
J Alvarez-Nemegyei, A Cobarrubias-Cobos, F Escalante-Triay, J Sosa-Muuoz, J M Miranda, and L J Jara
Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
Lupus, July 1, 1998; 7(6): 414 - 419.
[Abstract] [PDF]


Home page
J Biol RhythmsHome page
R. J. Nelson and J. M. C. Blom
Photoperiodic Effects on Tumor Development and Immune Function
J Biol Rhythms, December 1, 1994; 9(3-4): 233 - 249.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society